Correspondence 0001193125-25-336469 from Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc.
Date: Dec. 30, 2025 · CIK: 0001544227 · Accession: 0001193125-25-336469
AI Filing Summary & Sentiment
File numbers found in text: 333-292026
Letter
Re: Tempest Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-292026) Request for Acceleration of Effective Date Mr. Crawford and Ms. Crotty: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-292026) (the “ Registration Statement ”) to become effective on December 31, 2025, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Asa Henin and Jaime Chase of Cooley LLP to make such a request on its behalf. Once the Registration Statement has been declared effective, please confirm that event with Asa Henin of Cooley LLP, counsel to the Registrant, at (858) 550-6104 or ahenin@cooley.com, or in his absence, Jaime Chase, at (202) 728-7096 or jchase@cooley.com. [Signature page follows]
T EMPEST T HERAPEUTICS , I NC . 2000 Sierra Point Parkway, Suite 400 Brisbane, California December 30, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Attn: Mr. Daniel Crawford Ms. Laura Crotty
Very truly yours,
Tempest Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP T EMPEST T HERAPEUTICS , I NC . 2000 Sierra Point Parkway, Suite 400 Brisbane, California December 30, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Daniel Crawford Ms. Laura Crotty Re: Tempest Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-292026) Request for Acceleration of Effective Date Mr. Crawford and Ms. Crotty: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-292026) (the “ Registration Statement ”) to become effective on December 31, 2025, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Asa Henin and Jaime Chase of Cooley LLP to make such a request on its behalf. Once the Registration Statement has been declared effective, please confirm that event with Asa Henin of Cooley LLP, counsel to the Registrant, at (858) 550-6104 or ahenin@cooley.com, or in his absence, Jaime Chase, at (202) 728-7096 or jchase@cooley.com. [Signature page follows] Very truly yours, Tempest Therapeutics, Inc. By: /s/ Stephen Brady Stephen Brady Chief Executive Officer cc: Nicholas Maestas, Tempest Therapeutics, Inc. Asa Henin, Cooley LLP Jaime Chase, Cooley LLP Signature Page to Company Acceleration Request – S-1